EANS-Adhoc: Marseille-Kliniken AG / - Turnover growth of 5.6 % in first half of 2009/2010 totalling EUR 123.8 million - Earnings per share improve from EUR 0.08 to EUR 0.25 - Continued improvement of earnings expected

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

08.02.2010

Berlin, 8 February 2010. Marseille-Kliniken AG (Prime Standard, ISIN DE
0007783003, MKA) increased operating turnover in the first half of the financial
year 2009/2010 (1 July 2009 - 31 December 2009) by 5.6 % to EUR 123.8 million
(previous year: EUR 117.2 million). Group net income before minority interests
rose by EUR 2.3 million compared to the previous year - from EUR 0.8 million to
EUR 3.1 million. Earnings per share was also up, reaching EUR 0.25 compared to
EUR 0.08 in the previous year. EBIT/IFRS followed the trend, amounting to EUR
6.9 million compared to EUR 4.2 million in the previous year. EBITDAR/IFRS
increased to EUR 35.0 million from EUR 31.7 million. Equity however decreased
from EUR 79.5 million to EUR 65.0 million. This led to a decreased equity ratio
of 29.5 % compared to 35.2 % last year. Debt however also fell from EUR 77.2
million to EUR 76.1 million. The positive development of these business figures
show that the Group´s intense activities in the areas of marketing and cost
optimisation continue to stabilise.

Adjusted Group net income according to DVFA/SG (IFRS) decrease from EUR 6.0
million in the first half of previous year to EUR 5.6 million. This corresponds
to EUR 0.46 a share compared to EUR 0.49 last year. The lower earnings posted by
the acute hospital in Büren and increased tax expenses were notable factors in
this development. Adjusted EBITDAR meanwhile remained nearly unchanged at EUR
32.5 million after reaching EUR 32.7 million in the previous year. Adjusted EBIT
amounted to EUR 8.6 million (previous year: EUR 9.0 million). Occupancy levels
remained consistently high although capacity being increased by 287 beds. At the
Group level, occupancy reached 92.8 % with 9,387 beds (previous year: 92.7 %
with 9,100 beds).

As of the reporting date, capacity in the Care segment had increased from 7,771
beds to 8,058 beds as a result of expansions at the Waldkirch, Oberhausen and
Bremerhaven sites. The Group´s entire capacity expansion is therefore only
attributable to this segment. Turnover for the segment increased compared to the
previous year from EUR 90.5 million to EUR 95.4 million. Two facilities
negatively affected earnings according to DVFA/SG (IFRS) - bringing them down to
EUR 4.7 million after amounting to EUR 4.9 million in the previous year. These
facilities were still qualified as start-up facilities last year. The occupancy
rate in Care amounted to 92.4 % after previously totalling 92.7 %.

Capacity in the Rehabilitation segment remained unchanged at 1,329 beds while
turnover increased from EUR 26.6 million to EUR 28.4 million in the current
reporting period. Earnings according to DVFA/SG (IFRS) fell slightly from EUR
1.1 million to EUR 0.9 million. The occupancy rate for the segment however rose
from 92.5 % to 95.0 %.

Cost reduction measures will continue and Marseille-Kliniken is expecting
increasing earnings from a project on optimising material costs in particular.
The Group is also expecting further improvements on the income side, as it is
now focussing on increasing occupancy levels at every facility after having
completed a phase dedicated to opening new care facilities. An increase in
occupancy is expected, in particular for the expansion facilities which had
previously been responsible for negatively impacting earnings. Against this
backdrop, the company expects the momentum gained in the first half of the year
to remain throughout the coming two quarters.

For more detailed information, please visit the website
www.marseille-kliniken.com to read the quarterly report.

End of the ad hoc release

Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Germany
Tel.: +49-(0)30 / 246 32-400
Fax: +49-(0)30 / 246 32-401
www.marseille-kliniken.com

Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:   Marseille-Kliniken AG
          Alte Jakobstraße 79/80
          D-10709 Berlin
phone:    +49 (0)30 246 32-400 
FAX:      +49 (0)30 246 32-401
mail:     [email protected]
WWW:      http://www.marseille-kliniken.de
sector:   Pharmaceuticals
ISIN:     DE0007783003
indexes:  CDAX, Classic All Share, Prime All Share

stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Stuttgart, Düsseldorf, regulated dealing: Hamburg
language: English

Digitale Pressemappe: http://www.ots.at/pressemappe/EASY_7994

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print